PL3341380T3 - Penetrująca do mózgu pochodna oksymu kromonu do terapii dyskinesy wywołanej przez lewodopę - Google Patents
Penetrująca do mózgu pochodna oksymu kromonu do terapii dyskinesy wywołanej przez lewodopęInfo
- Publication number
- PL3341380T3 PL3341380T3 PL16769872T PL16769872T PL3341380T3 PL 3341380 T3 PL3341380 T3 PL 3341380T3 PL 16769872 T PL16769872 T PL 16769872T PL 16769872 T PL16769872 T PL 16769872T PL 3341380 T3 PL3341380 T3 PL 3341380T3
- Authority
- PL
- Poland
- Prior art keywords
- levodopa
- penetrant
- brain
- therapy
- oxime derivative
- Prior art date
Links
- 208000012661 Dyskinesia Diseases 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- IPDGWIYTNQXKSP-UHFFFAOYSA-N n-chromen-4-ylidenehydroxylamine Chemical class C1=CC=C2C(=NO)C=COC2=C1 IPDGWIYTNQXKSP-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/069601 WO2016030444A1 (en) | 2014-08-27 | 2015-08-27 | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| EP15188368 | 2015-10-05 | ||
| PCT/EP2016/070175 WO2017032874A1 (en) | 2015-08-27 | 2016-08-26 | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
| EP16769872.9A EP3341380B1 (en) | 2015-08-27 | 2016-08-26 | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3341380T3 true PL3341380T3 (pl) | 2020-04-30 |
Family
ID=54260666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16769872T PL3341380T3 (pl) | 2015-08-27 | 2016-08-26 | Penetrująca do mózgu pochodna oksymu kromonu do terapii dyskinesy wywołanej przez lewodopę |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10532057B2 (pl) |
| EP (2) | EP3341380B1 (pl) |
| JP (1) | JP2018528205A (pl) |
| KR (1) | KR20180041234A (pl) |
| CN (1) | CN108349993A (pl) |
| AU (1) | AU2016313138A1 (pl) |
| CA (1) | CA2995313A1 (pl) |
| CL (1) | CL2018000497A1 (pl) |
| CY (1) | CY1122401T1 (pl) |
| DK (1) | DK3341380T3 (pl) |
| DO (1) | DOP2018000060A (pl) |
| EA (1) | EA035016B1 (pl) |
| ES (1) | ES2764490T3 (pl) |
| HR (1) | HRP20192250T1 (pl) |
| HU (1) | HUE047531T2 (pl) |
| IL (1) | IL257655A (pl) |
| LT (1) | LT3341380T (pl) |
| MA (1) | MA42700B1 (pl) |
| ME (1) | ME03591B (pl) |
| MX (1) | MX2018002255A (pl) |
| NI (1) | NI201800031A (pl) |
| PH (1) | PH12018500430A1 (pl) |
| PL (1) | PL3341380T3 (pl) |
| PT (1) | PT3341380T (pl) |
| RS (1) | RS59651B1 (pl) |
| RU (1) | RU2018110580A (pl) |
| SI (1) | SI3341380T1 (pl) |
| SM (1) | SMT201900720T1 (pl) |
| TN (1) | TN2018000061A1 (pl) |
| WO (1) | WO2017032874A1 (pl) |
| ZA (1) | ZA201801642B (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900152T1 (it) | 2014-08-27 | 2019-05-10 | Prexton Therapeutics Sa | Nuovo derivato di cromone ossima e suo uso come modulatore allosterico di recettori metabotropici del glutammato |
| AU2016313138A1 (en) | 2015-08-27 | 2018-03-15 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
| IL280213B2 (en) | 2018-07-26 | 2024-06-01 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| US11954413B2 (en) | 2018-12-14 | 2024-04-09 | Hewlett-Packard Development Company, L.P. | Evaluating candidate virtual build volumes |
| GB202016425D0 (en) * | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
| CN115594655B (zh) * | 2022-09-16 | 2023-08-15 | 桂林医学院 | 色酮肟类衍生物及其制备方法和应用 |
| WO2024117683A1 (ko) * | 2022-11-30 | 2024-06-06 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| JP3993651B2 (ja) | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (en) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Process for producing 4-sustituted benzopyran derivatives |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| JP2006522124A (ja) | 2003-04-03 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用な組成物 |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| WO2007011701A1 (en) | 2005-07-15 | 2007-01-25 | Transform Pharmaceuticals, Inc. | Novel hydrochloride salts of levodopa |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| WO2009010455A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as modulators of metabotropic glutamate receptors |
| JP5806672B2 (ja) | 2009-10-30 | 2015-11-10 | ドメイン・セラピューティクス | 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用 |
| KR102074089B1 (ko) | 2009-12-04 | 2020-02-05 | 선오비온 파마슈티컬스 인코포레이티드 | 다환형 화합물 및 이의 사용 방법 |
| WO2011107653A2 (en) * | 2010-03-04 | 2011-09-09 | Orion Corporation | Method for treating parkinson's disease |
| SMT201900152T1 (it) * | 2014-08-27 | 2019-05-10 | Prexton Therapeutics Sa | Nuovo derivato di cromone ossima e suo uso come modulatore allosterico di recettori metabotropici del glutammato |
| AU2016313138A1 (en) | 2015-08-27 | 2018-03-15 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
-
2016
- 2016-08-26 AU AU2016313138A patent/AU2016313138A1/en not_active Abandoned
- 2016-08-26 PT PT167698729T patent/PT3341380T/pt unknown
- 2016-08-26 KR KR1020187008542A patent/KR20180041234A/ko not_active Withdrawn
- 2016-08-26 RS RS20191571A patent/RS59651B1/sr unknown
- 2016-08-26 JP JP2018510876A patent/JP2018528205A/ja active Pending
- 2016-08-26 LT LTEP16769872.9T patent/LT3341380T/lt unknown
- 2016-08-26 CN CN201680062784.8A patent/CN108349993A/zh active Pending
- 2016-08-26 HR HRP20192250TT patent/HRP20192250T1/hr unknown
- 2016-08-26 SI SI201630559T patent/SI3341380T1/sl unknown
- 2016-08-26 EP EP16769872.9A patent/EP3341380B1/en active Active
- 2016-08-26 EP EP19207959.8A patent/EP3696182A1/en not_active Withdrawn
- 2016-08-26 WO PCT/EP2016/070175 patent/WO2017032874A1/en not_active Ceased
- 2016-08-26 DK DK16769872.9T patent/DK3341380T3/da active
- 2016-08-26 ES ES16769872T patent/ES2764490T3/es active Active
- 2016-08-26 ME MEP-2019-346A patent/ME03591B/me unknown
- 2016-08-26 EA EA201890590A patent/EA035016B1/ru not_active IP Right Cessation
- 2016-08-26 PL PL16769872T patent/PL3341380T3/pl unknown
- 2016-08-26 MA MA42700A patent/MA42700B1/fr unknown
- 2016-08-26 SM SM20190720T patent/SMT201900720T1/it unknown
- 2016-08-26 TN TNP/2018/000061A patent/TN2018000061A1/en unknown
- 2016-08-26 HU HUE16769872A patent/HUE047531T2/hu unknown
- 2016-08-26 CA CA2995313A patent/CA2995313A1/en not_active Abandoned
- 2016-08-26 RU RU2018110580A patent/RU2018110580A/ru not_active Application Discontinuation
- 2016-08-26 US US15/755,435 patent/US10532057B2/en not_active Expired - Fee Related
- 2016-08-26 MX MX2018002255A patent/MX2018002255A/es unknown
-
2018
- 2018-02-21 IL IL257655A patent/IL257655A/en unknown
- 2018-02-23 NI NI201800031A patent/NI201800031A/es unknown
- 2018-02-23 CL CL2018000497A patent/CL2018000497A1/es unknown
- 2018-02-26 DO DO2018000060A patent/DOP2018000060A/es unknown
- 2018-02-27 PH PH12018500430A patent/PH12018500430A1/en unknown
- 2018-03-09 ZA ZA2018/01642A patent/ZA201801642B/en unknown
-
2019
- 2019-12-10 CY CY20191101297T patent/CY1122401T1/el unknown
- 2019-12-11 US US16/709,988 patent/US20200171042A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001012B (en) | Method of targeting exosomes | |
| EP3268657A4 (en) | Magnetic mount system | |
| GB201608825D0 (en) | Compressor system | |
| ZA201801642B (en) | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia | |
| EP3275321A4 (en) | Flavor inhaler | |
| EP3185970A4 (en) | Self-optimising respiratory therapy system | |
| EP3284354A4 (en) | Flavor inhaler | |
| GB201500463D0 (en) | Therapeutic molecules | |
| GB2539065B (en) | Pre-filter fragmentation | |
| GB201500461D0 (en) | Therapeutic molecules | |
| PL3338032T3 (pl) | System uzdatniania powietrza | |
| EP3265159A4 (en) | Cranium cuddler | |
| GB201505747D0 (en) | Exosomes | |
| EP3278021A4 (en) | Desuperheater system | |
| GB2555064B (en) | Refrigeration system | |
| EP3294875B8 (en) | Icp0-mediated enhanced expression system | |
| EP3362538A4 (en) | HYPERGOLIC SYSTEM | |
| SG11201708354WA (en) | Gas therapy system | |
| EP3305311A4 (en) | Brain function-protecting agent | |
| EP3386629A4 (en) | Fluid treatment system | |
| ZA202004030B (en) | Personal progressive jackpot system | |
| HK40034221A (en) | Method of targeting exosomes | |
| GB201721453D0 (en) | Argonaute system | |
| GB2550001B (en) | An Equaliser Controlled Compressor System | |
| GB201712656D0 (en) | Argonaute system |